Very recent onset rheumatoid arthritis: clinical and serological patient characteristics associated with radiographic progression over the first years of disease

被引:246
作者
Machold, K. P. [1 ]
Stamm, T. A.
Nell, V. P. K.
Pflugbeil, S.
Aletaha, D.
Steiner, G.
Uffmann, M.
Smolen, J. S.
机构
[1] Med Univ Vienna, Dept Rheumatol, Vienna, Austria
[2] Hietzing Municipal Hosp, Dept Med 2, Vienna, Austria
[3] NIAMS, Mark O Hatfield Clin Res Ctr, NIH, Bethesda, MD USA
[4] Med Univ Vienna, Dept Radiol, Vienna, Austria
关键词
very early rheumatoid arthritis; determinants of radiographic progression; disease control;
D O I
10.1093/rheumatology/kel237
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Objectives. Despite early recognition and disease modifying anti-rheumatic drug ( DMARD) treatment, a sizable proportion of early rheumatoid arthritis (RA) patients show radiological progression. This study was performed to determine the frequency of erosive arthritis and the pace of radiological progression in an inception cohort of patients with very early RA (<= 3 months after onset of symptoms). Methods. In order to determine possible prognostic factors for development of erosive disease, we linked the clinical features of these patients to radiological progression in a regression model. About 55 patients with RA and follow-up of at least 3 yrs were analysed. All had complete series of clinical, serological and radiographic assessments. Radiographs were scored according to the Larsen method. Results. Erosive disease developed in 63.6% of the patients over 3 yrs, with the majority (74.3%) appearing already in the first and 97.2% by the end of the second year. Among all variables available, rheumatoid factor (RF) and/or anti-cyclic citrullinated peptide (anti-CCP) first presentation were the most predictive for both development of erosions and the degree of radiological progression. None of the clinical variables at the onset was useful to discriminate between erosive and non-erosive patients. In the final regression model, however, cumulative clinical activity substantially contributed to explaining radiological progression. Conclusion. Despite early treatment, substantial damage occurred in some patients and was associated with presence of strong 'constitutive' predictors such as anti-CCP and RF as well as presence of high long-term clinical disease activity as indicated by C-reactive protein (CRP), swollen joint counts and the absence of a good clinical response (assessed by the failure to achieve lasting low disease activity).
引用
收藏
页码:342 / 349
页数:8
相关论文
共 42 条
[1]
WHEN DOES RHEUMATOID DISEASE START [J].
AHO, K ;
PALOSUO, T ;
RAUNIO, V ;
PUSKA, P ;
AROMAA, A ;
SALONEN, JT .
ARTHRITIS AND RHEUMATISM, 1985, 28 (05) :485-489
[2]
Remission and active disease in rheumatoid arthritis - Defining criteria for disease activity states [J].
Aletaha, D ;
Ward, MM ;
Machold, KP ;
Nell, VPK ;
Stamm, T ;
Smolen, JS .
ARTHRITIS AND RHEUMATISM, 2005, 52 (09) :2625-2636
[3]
Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score [J].
Aletaha, D ;
Nell, VP ;
Stamm, T ;
Uffmann, M ;
Pflugbeil, S ;
Machold, K ;
Smolen, JS .
ARTHRITIS RESEARCH & THERAPY, 2005, 7 (04) :R796-R806
[4]
Attitudes to early rheumatoid arthritis: changing patterns. Results of a survey [J].
Aletaha, D ;
Eberl, G ;
Nell, VPK ;
Machold, KP ;
Smolen, JS .
ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 (10) :1269-1275
[5]
A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis [J].
Bathon, JM ;
Martin, RW ;
Fleischmann, RM ;
Tesser, JR ;
Schiff, MH ;
Keystone, EC ;
Genovese, MC ;
Wasko, MC ;
Moreland, LW ;
Weaver, AL ;
Markenson, J ;
Finck, BK .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (22) :1586-1593
[6]
The PREMIER study - A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment [J].
Breedveld, FC ;
Weisman, MH ;
Kavanaugh, AF ;
Cohen, SB ;
Pavelka, K ;
van Vollenhoven, R ;
Sharp, J ;
Perez, JL ;
Spencer-Green, GT .
ARTHRITIS AND RHEUMATISM, 2006, 54 (01) :26-37
[7]
Bruynesteyn K, 2002, J RHEUMATOL, V29, P2306
[8]
Combination of infliximab and methotrexate therapy for early rheumatoid arthritis - A randomized, controlled trial [J].
Clair, EWS ;
van der Heijde, DMFM ;
Smolen, JS ;
Maini, RN ;
Bathon, JM ;
Emery, P ;
Keystone, E ;
Schiff, M ;
Kalden, JR ;
Wang, B ;
DeWoody, K ;
Weiss, R ;
Baker, D .
ARTHRITIS AND RHEUMATISM, 2004, 50 (11) :3432-3443
[9]
Edmonds J, 1999, J RHEUMATOL, V26, P740
[10]
Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria [J].
Fransen, J ;
Creemers, MCW ;
Van Riel, PLCM .
RHEUMATOLOGY, 2004, 43 (10) :1252-1255